We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sourcebio International Plc | LSE:SBI | London | Ordinary Share | GB00BKSB1674 | ORD GBP0.0015 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 115.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 105.00 | 150.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 115.00 | GBX |
Sourcebio (SBI) Share Charts1 Year Sourcebio Chart |
|
1 Month Sourcebio Chart |
Intraday Sourcebio Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/6/2023 | 18:55 | SOURCE BIO INTERNATIONAL | 579 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 29/12/2022 11:21 by supernumerary finkie - don't be so lazy!'As previously announced on 23 November 2022, following the approval of the proposed Cancellation by Shareholders at the General Meeting held today, the last day of dealings in the Company's Ordinary Shares on AIM will be 29 December 2022 and the Cancellation will become effective at 7:00 a.m. on 30 December 2022, subject to a Dealing Notice, as defined in the AIM Rules for Companies, being issued. The Re-Registration of the Company as a private company is expected to take place on or around 18 January 2023.' yes yes; but 'at a lower price' makes no sense 9degrees - yes, farewell indeed. Been in and out here in the past, and was contemplating buying a chunk again, but saved by the bell. I suspect, however, they'll be back in some form or other... |
Posted at 29/12/2022 10:09 by 9degrees Good bye SBI I feel i have been ripped off whatever their good intentions |
Posted at 17/12/2022 21:55 by finkie And a further question what happens to investors buying stock and holding at 100p do they still own a part of source bio as a private company but able to own at a lower price? |
Posted at 09/12/2022 14:23 by assword Just sold for 110 and moved on. Take the hit and learn a lesson or two. Thought best strike now with what little I got out of SBI to move for a stock awaiting results before end of Q4. At least I had the money to trade with now, rather than later. Hopefully it's a double bagger and I get back what I lost out on !!! |
Posted at 05/12/2022 17:15 by c3479z grim result having to accept 115 but the alternative is just too risky,chances are that it will reappear in a few years at a much higher price but this is not certain. |
Posted at 09/11/2022 08:11 by brummy_git Planned 115p/share tender offer for SourceBio shareholders, before going private.All the news here www.linkedin.com/pos |
Posted at 13/9/2022 14:24 by c3479z what disturbs is that the CFO gave a summary at the presentation without mentioning, as far as memory serves, that the group made a loss, reinforcing the cherry-picking approach also adopted at the results announcement where readers had to scan down almost towards the end of the announcement before this was disclosed.Do agree that there is plenty of opportunity in cellular pathology but the idea that a 24 hour turnaround time can be achieved across the board is false- it may be possible for the simplest specimens and biopsies to present digitised images to the pathologist within 24 hours but for more complex cases a period of specimen fixation, dissection, block selection and processing can mean a 4-5 day period between specimen receipt and slides being available, the overall turnaround time varies with the diligence of the pathologist who must fit in reporting with a number of other commitments,if they work in the NHS also- MDT meetings, post mortems, CPD, specimen dissection... plenty of competition for private work even if SBI and LD combined are the biggest provider: digitisation of slides not all that novel- it's happening also in the NHS where amalgamations between labs could eventually lead to a more efficient service/increased competition for SBI, with on-site molecular pathology/NGS also becoming standard. Agree there is a present global shortage of pathologists and increasing demand for cellular path as the population ages, more endoscopies done, skin biopsies and gynae specimens taken and more complex investigations required - seems that cellular path is not a highly popular specialty among medical graduates since pathology was de-emphasised at the medical schools but staffing tends to go in cycles though no present sign of improvement...especi Overall therefore outlook should be good for their cellular path division especially if they can integrate it with their genomics outfit. |
Posted at 08/9/2022 07:28 by samewe Let’s hope we will see some upwards movement on the share price to above 200p. |
Posted at 08/9/2022 07:14 by brummy_git Excellent H1 numbers, and positive outlook today from SourceBio's core divisions.All the details & commentary here www.linkedin.com/pos |
Posted at 05/4/2022 16:13 by james188 base7 - They paid for LDPath in cash because the share price is(and was)so low that it made no sense to pay in shares (even if the vendors had wanted to do that). Contrast that to the EKF acquisition of a US lab which was done when the EKF share price was pretty much double what it is now. That might also have been noticed.I think that the market reaction today has been relatively cautious because there will have to be a huge increase in the core business revenues - and healthcare diagnostics in particular - to replace the large hole left by the drop in revenues from infectious diseases testing. It was alway known that that was going to happen, but it is still a challenge. In my view, the management team deserves a lot of credit for spotting the COVID business opportunity and then executing it so well. They now need to repeat the trick and demonstrate that the price paid for LDPath was reasonable. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
